Showing 1411-1420 of 1576 results for "".
- J&J Expands Availability of Tecnis Odyssey PC-IOLhttps://modernod.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built
- Microsurgical Technology (MST) Announces Global Partnership with Vista Ophthalmicshttps://modernod.com/news/microsurgical-technology-mst-announces-global-partnership-with-vista-ophthalmics/2482446/Microsurgical Technology (MST) announced an exclusive global partnership with ophthalmic device company Vista Ophthalmics that will introduce Vista Ophthalmics' products—Vista 1-Step and Vista IS—to the global market. Financial terms of the deal were not disclosed.
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- ASCRS Launches Summit Designed to Enhance Refractive Cataract Surgery Practiceshttps://modernod.com/news/ascrs-launches-summit-designed-to-enhance-refractive-cataract-surgery-practices/2482384/In a move to enhance the adoption of advanced-technology IOLs (AT IOLs), the American Society of Cataract & Refractive Surgery (ASCRS) announced a new educational initiative—the ASCRS Business of Refractive Cataract Surgery Summit (BRiCS). The summit aims to equip practices with th
- J-Code for Glaukos’ iDose TR Becomes Activehttps://modernod.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.<
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T